Article: Reduced transverse relaxation rate (RR2) for improved sensitivity in monitoring myocardial iron in thalassemia

File Download Links for fulltext
(May Require Subscription)
Supplementary

  • Basic View
  • Metadata View
  • XML View
TitleReduced transverse relaxation rate (RR2) for improved sensitivity in monitoring myocardial iron in thalassemia
AuthorsCheung, JS
Au, WY
Ha, SY
Kim, D
Jensen, JH
Zhou, IY
Cheung, MM
Wu, Y
Guo, H
Khong, PL
Brown, TR
Brittenham, GM
Wu, EX
Keywordscardiac MR
chelation therapy
ferritin
heart
hemosiderin
iron overload
MRI
RR2
thalassemia
Issue Date2011
PublisherJohn Wiley & Sons, Inc. The Journal's web site is located at http://www.interscience.wiley.com/jpages/1053-1807/
CitationJournal Of Magnetic Resonance Imaging, 2011, v. 33 n. 6, p. 1510-1516 [How to Cite?]
DOI: http://dx.doi.org/10.1002/jmri.22553
AbstractPurpose: To evaluate the reduced transverse relaxation rate (RR2), a new relaxation index which has been shown recently to be primarily sensitive to intracellular ferritin iron, as a means of detecting short-term changes in myocardial storage iron produced by iron-chelating therapy in transfusion-dependent thalassemia patients. Materials and Methods: A single-breathhold multi-echo fast spin-echo sequence was implemented at 3 Tesla (T) to estimate RR2 by acquiring signal decays with interecho times of 5, 9 and 13 ms. Transfusion-dependent thalassemia patients (N = 8) were examined immediately before suspending iron-chelating therapy for 1 week (Day 0), after a 1-week suspension of chelation (Day 7), and after a 1-week resumption of chelation (Day 14). Results: The mean percent changes in RR2, R2, and R2* off chelation (between Day 0 and 7) were 11.9 ± 8.9%, 5.4 ± 7.7% and -4.4 ± 25.0%; and, after resuming chelation (between Day 7 and 14), -10.6 ± 13.9%, -8.9 ± 8.0% and -8.5 ± 24.3%, respectively. Significant differences in R2 and RR2 were observed between Day 0 and 7, and between Day 7 and 14, with the greatest proportional changes in RR2. No significant differences in R2* were found. Conclusion: These initial results demonstrate that significant differences in RR2 are detectable after a single week of changes in iron-chelating therapy, likely as a result of superior sensitivity to soluble ferritin iron, which is in close equilibrium with the chelatable cytosolic iron pool. RR2 measurement may provide a new means of monitoring the short-term effectiveness of iron-chelating agents in patients with myocardial iron overload. Copyright © 2011 Wiley-Liss, Inc.
ISSN1053-1807
2011 Impact Factor: 2.698
2011 SCImago Journal Rankings: 0.242
DOIhttp://dx.doi.org/10.1002/jmri.22553
PubMed Central IDPMC3098046
ReferencesReferences in Scopus
DC Field
Value
dc.contributor.authorCheung, JS
dc.contributor.authorAu, WY
dc.contributor.authorHa, SY
dc.contributor.authorKim, D
dc.contributor.authorJensen, JH
dc.contributor.authorZhou, IY
dc.contributor.authorCheung, MM
dc.contributor.authorWu, Y
dc.contributor.authorGuo, H
dc.contributor.authorKhong, PL
dc.contributor.authorBrown, TR
dc.contributor.authorBrittenham, GM
dc.contributor.authorWu, EX
dc.date.accessioned2011-09-23T05:45:34Z
dc.date.available2011-09-23T05:45:34Z
dc.date.issued2011
dc.description.abstractPurpose: To evaluate the reduced transverse relaxation rate (RR2), a new relaxation index which has been shown recently to be primarily sensitive to intracellular ferritin iron, as a means of detecting short-term changes in myocardial storage iron produced by iron-chelating therapy in transfusion-dependent thalassemia patients. Materials and Methods: A single-breathhold multi-echo fast spin-echo sequence was implemented at 3 Tesla (T) to estimate RR2 by acquiring signal decays with interecho times of 5, 9 and 13 ms. Transfusion-dependent thalassemia patients (N = 8) were examined immediately before suspending iron-chelating therapy for 1 week (Day 0), after a 1-week suspension of chelation (Day 7), and after a 1-week resumption of chelation (Day 14). Results: The mean percent changes in RR2, R2, and R2* off chelation (between Day 0 and 7) were 11.9 ± 8.9%, 5.4 ± 7.7% and -4.4 ± 25.0%; and, after resuming chelation (between Day 7 and 14), -10.6 ± 13.9%, -8.9 ± 8.0% and -8.5 ± 24.3%, respectively. Significant differences in R2 and RR2 were observed between Day 0 and 7, and between Day 7 and 14, with the greatest proportional changes in RR2. No significant differences in R2* were found. Conclusion: These initial results demonstrate that significant differences in RR2 are detectable after a single week of changes in iron-chelating therapy, likely as a result of superior sensitivity to soluble ferritin iron, which is in close equilibrium with the chelatable cytosolic iron pool. RR2 measurement may provide a new means of monitoring the short-term effectiveness of iron-chelating agents in patients with myocardial iron overload. Copyright © 2011 Wiley-Liss, Inc.
dc.description.naturelink_to_OA_fulltext
dc.identifier.citationJournal Of Magnetic Resonance Imaging, 2011, v. 33 n. 6, p. 1510-1516 [How to Cite?]
DOI: http://dx.doi.org/10.1002/jmri.22553
dc.identifier.doihttp://dx.doi.org/10.1002/jmri.22553
dc.identifier.epage1516
dc.identifier.hkuros192054
dc.identifier.isiWOS:000291267700028
Funding AgencyGrant Number
Hong Kong Research Grant CouncilGRF7794/07M
Hong Kong Children Thalassaemia Foundation2007/02
National Institutes of HealthR01-DK069373
R01-DK066251
R37-DK049108
R01-DK049108
American Heart Association0730143N
Funding Information:

Contract grant sponsor: Hong Kong Research Grant Council; Contract grant number: GRF7794/07M; Contract grant sponsor: Hong Kong Children Thalassaemia Foundation; Contract grant number: 2007/02; Contract grant sponsor: National Institutes of Health; Contract grant numbers: R01-DK069373, R01-DK066251, R37-DK049108, R01-DK049108; Contract grant sponsor: American Heart Association; Contract grant number: 0730143N.

dc.identifier.issn1053-1807
2011 Impact Factor: 2.698
2011 SCImago Journal Rankings: 0.242
dc.identifier.issue6
dc.identifier.pmcidPMC3098046
dc.identifier.pmid21591022
dc.identifier.scopuseid_2-s2.0-79958254314
dc.identifier.spage1510
dc.identifier.urihttp://hdl.handle.net/10722/139127
dc.identifier.volume33
dc.languageeng
dc.publisherJohn Wiley & Sons, Inc. The Journal's web site is located at http://www.interscience.wiley.com/jpages/1053-1807/
dc.publisher.placeUnited States
dc.relation.ispartofJournal of Magnetic Resonance Imaging
dc.relation.referencesReferences in Scopus
dc.rightsJournal of Magnetic Resonance Imaging. Copyright © John Wiley & Sons, Inc.
dc.subject.meshBlood Transfusion
dc.subject.meshChelating Agents - pharmacology
dc.subject.meshIron - chemistry
dc.subject.meshMyocardium - pathology
dc.subject.meshThalassemia - diagnosis - pathology
dc.subjectcardiac MR
dc.subjectchelation therapy
dc.subjectferritin
dc.subjectheart
dc.subjecthemosiderin
dc.subjectiron overload
dc.subjectMRI
dc.subjectRR2
dc.subjectthalassemia
dc.titleReduced transverse relaxation rate (RR2) for improved sensitivity in monitoring myocardial iron in thalassemia
dc.typeArticle
Author Affiliations
  1. Massachusetts General Hospital
  2. New York University School of Medicine
  3. Columbia University in the City of New York
  4. The University of Hong Kong
  5. Columbia University, College of Physicians and Surgeons
  6. Tsinghua University